# Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED

> **NCT04338828** · PHASE2 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 47 (actual)

## Conditions studied

- COVID19

## Interventions

- **DRUG:** Nitric Oxide Gas
- **OTHER:** Inhaled Supplemental Oxygen

## Key facts

- **NCT ID:** NCT04338828
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-18
- **Primary completion:** 2021-01-14
- **Final completion:** 2021-03-01
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Absence of patients meeting criteria following initial COVID surge. DMSB recommended analysis of results to date and early closure.
- **Last updated:** 2022-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04338828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04338828, "Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04338828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*